Exenatide
Exenatide (Byetta/Bydureon)
Exenatide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist derived from the salivary peptide exendin-4, originally isolated from the Gila monster. It is FDA-approved for the treatment of type 2 diabetes mellitus to improve glycemic control, and is also used off-label for weight management. It is available as a twice-daily injection (Byetta) and a once-weekly extended-release formulation (Bydureon).
Mechanism of Action
Exenatide binds to and activates the GLP-1 receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion and suppressing inappropriately elevated glucagon levels, thereby lowering blood glucose. It also slows gastric emptying, reducing postprandial glucose spikes, and acts on hypothalamic centers to promote satiety and reduce food intake. These combined effects produce meaningful reductions in HbA1c (typically 0.5–1.5%) and body weight.
Evidence by Health Goal(18 goals)
Dosing Protocols
Within 60 minutes before morning and evening meals
Starting dose of 5mcg twice daily for at least 4 weeks to improve tolerability. Administered subcutaneously in the abdomen, thigh, or upper arm. This is the Byetta (immediate-release) protocol.
Within 60 minutes before morning and evening meals
Maintenance dose of 10mcg twice daily after initial 4-week titration period with 5mcg. Can further improve glycemic control and weight loss outcomes. This is the standard Byetta maintenance protocol.
Any time of day, with or without food; same day each week
Extended-release microsphere formulation (Bydureon). No titration required. Inject subcutaneously in abdomen, thigh, or upper arm. Day of week may be changed if last dose was 3+ days prior.
Safety & Side Effects
Exenatide has a well-characterized safety profile over 15+ years of clinical use, but it is a prescription-only medication in all major jurisdictions and should not be used without medical supervision. It carries FDA black box warnings in the extended-release form regarding a potential risk of thyroid C-cell tumors observed in rodents (clinical significance unclear), and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2, as well as in severe renal impairment (eGFR <30 mL/min).
Possible Side Effects
- !Nausea (most common, affects up to 44% of patients, typically transient and dose-dependent)
- !Vomiting, particularly early in treatment or following dose escalation
- !Diarrhea and loose stools, especially during initiation
- !Injection site reactions including nodules, redness, or pruritus (more common with Bydureon)
- !Hypoglycemia, particularly when combined with sulfonylureas or insulin
- !Decreased appetite and early satiety
- !Headache and dizziness
- !Acute pancreatitis (rare but serious; discontinue if suspected)
Interactions
- -Sulfonylureas (e.g., glipizide, glimepiride): significantly increases hypoglycemia risk; reduce sulfonylurea dose when combining
- -Insulin: concurrent use increases hypoglycemia risk; dose adjustment of basal insulin required
- -Oral medications with narrow therapeutic windows (e.g., warfarin, antibiotics): gastric emptying delay may alter absorption timing and peak concentrations
- -Warfarin: case reports of increased INR; monitor closely when initiating or adjusting exenatide
- -Alcohol: may potentiate hypoglycemia risk, especially in patients on concomitant insulin or secretagogues
Cost & Where to Buy
Brand-name Byetta and Bydureon are expensive without insurance; monthly costs often $650–$900 retail. With insurance or manufacturer copay cards, out-of-pocket cost can be reduced to $25–$100/month. No FDA-approved generic is currently available in the US. Research-grade exenatide from peptide vendors costs significantly less ($50–$150/month) but lacks pharmaceutical oversight and is not intended for human use.
Search on Amazon